BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:4th Annual Pharma Regulatory Summit 2021\n\n18th March 2021\, Virtual Conference (Time Zone - IST)\n\n \;\n\nGreetings from Virtue Insight\, \n\nJoin 4th Annual Pharma Regulatory Summit 2021 virtual confe rence and engage in a series of strategic discussions on current regulato ry landscape\, globalization\, and harmonization initiatives in India. Vi rtue Insight brings you an interactive dynamics\, where you will be engag ed in discussions with key stakeholders influencing the advancement and i mplementation of regulatory convergence initiatives. Join us to discuss m ulti-regional cooperation\, global harmonization\, and best practices rel ated to India’s regulatory landscape. Sessions will highlight regulatory approaches and good practices to ensure certainty in India and strategic initiatives to improve collaboration and cooperation.\n\nDELEGATE REGISTR ATION:\n\nE-mail - kavitha@virtueinsight.co.in or Call M: +91 9940791115\ n\nPlease note that this is a PAID event and NOT A FREE event (no complim entary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party s ite will strictly not be accepted by the organizer.  \;\n\n\nEarly Bi rd Price (Till 2nd February 2021) – (INR 6\,000 + GST (18%) per delegate) \nStandard Price (From 3rd February 2021) – (INR 8\,000 + GST (18%) per d elegate)\nFor more than 5 delegates please let us know your interests.\n\ nConference Sponsor\, Exhibition Stall &\; Paid Speaker Slot - Please email your interest and queries to kavitha@virtueinsight.co.in\n\nKEY SPE AKERS:\n\n\nRAJENDRA SANGHAVI\, Sr. Consulting Clinician / Expert - Medic oMarketing &\; TechnoLegal (Healthcare) / Chairman - Nutraceutical Com mittee\, (IDMA)\nSADHNA JOGLEKAR\, Senior Vice President\, Global Medical Affairs\, Sun pharma\nYASMIN SHENOY\, Director-Regulatory Affairs\, Sano fi-aventis\n\n\nRAHUL GUPTA\, Vice President\, Regulatory Affairs\, USV\n \n\nPRATIK SHAH\, Vice President - Medical Affairs\, Bharat Serums and Va ccines\nRASHMI HEGDE\, Vice President Medical\, Cipla\nDEEPA ARORA\, Dire ctor\, CLINEXEL Life Sciences\nMILIND NARVEKAR\, Vice President Global Re gulatory Affairs\, Teva Pharmaceuticals\nSHARADD JAIN\, Vice President\, Cipla\nASHISH GAWDE\, Country Medical Director\, Bayer Pharmaceuticals\nA MEY MANE\, Director-Medical Affairs\, Dr. Reddy’s Laboratories\nSHIRAZ KA NDAWALLA\, Associate Director - Regulatory Affairs\, Abbott\nDILIP PAWAR\ , Global Head Medical Affairs and Pharmacovigilance\, Unichem Laboratorie s\nARIF KHAN\, Head – Regulatory Affairs\, Pharmacovigilance and Medical Information\, UCB\nSANDEEP ARORA\, Medical Affairs Head\, Takeda\nNANDAN JOSHI\, Head Medical Affairs - Nutrition\, India and Emerging Markets\, D r. Reddy's Laboratories\nHARSHAD KOTHAWADE\, Head of Regulatory Managemen t &\; Trade Compliance\, Merck group\nMINOO BIJU\, Head-Regulatory Aff airs\, Piramal Pharma Solutions\nSANJEEV KUMAR\, Head- Regulatory Externa l Manufacturing\, Sanofi\nAMITA BHAVE\, Head Regulatory Affairs GDD India \, Novartis\nMANISH MAHAJAN\, Head- Medical Affairs\, Cadila Healthcare ( BU- Biologics)\nSOFI JOSEPH\, Head of Regulatory Affairs and Pharmacovigi lance\, Serdia Pharmaceuticals\nVARSHA NARAYANAN\, Founder-Director &\ ; Senior Consultant Medical Affairs\, Dr Varsha’s Health Solutions\nVISHW AS SOVANI\, Founder Director\, Pharmawisdom \n\nPlus more joining soon\n\ n \;\n\nKEY THEMES DISCUSSED:\n\n \;\n\n\nAssure access to medica tions: How will regulatory weaknesses in pharmaceuticals be addressed?\nP olitical landscape: how could medical policy be affected?\nAddressing pol itical mechanisms and advantages intended to regulate the business.\nPres ent regulatory system for the growth and effective production of medicina l products in scientific and technological ways\nDiscussing how to ensure operational performance in compliance with the aim of better regulation. \nRegulatory and consumer opportunities for patients to approve and retai n critical drugs\nAddressing existing problems in the growth of more comp lex off-patent medicinal products\nRegulatory structure for complex off-p atent drugs\, from the viewpoint of global product growth\nRegulatory cha llenges for medical devices\nDiscussing the efficiency of the devices and regulatory initiatives\nPriorities of new Indian Commission's policies r elevant to pharmaceuticals\nAddressing the Indian System of Medicine's ac ceptance of the new medical science by health personnel.\nReal word evide nce: How it could be used to facilitate regulatory decision-making\nAddre ssing patient's health and health care delivery data that are regularly o btained from a number of sources\nPossible legislative options to help mi nimise the risk of shortages and to reduce them\nAddressing the problem a s well as other supply chain issues\nInitiatives of regulatory convergenc e – How the regulators and stakeholders of medical products may benefit f rom the guidance and convergence activities in India.\nGuidelines for nat ional regulatory authorities for medical products\nBe part of a major net working opportunity\n\n \;\n\nGet more from the event\, with a broade r scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the lea ding international vendors showcasing the products of tomorrow in the co- located exhibition.\n\n \;\n\n \;\n DTEND:20210318T173000 DTSTAMP:20260512T231939Z DTSTART:20210318T093000 LOCATION:\, SEQUENCE:0 SUMMARY:4th Annual Pharma Regulatory Summit 2021\n18th March 2021\, Virtua l Conference (Time Zone - IST)\n \;\nGreetings from Virtue Insight\, \nJoin 4th... UID:75dfd87d-6b60-421e-9c01-5eb9ea9e8bb0 END:VEVENT END:VCALENDAR